CLINICAL TRIALS PROFILE FOR BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
✉ Email this page to a colleague
All Clinical Trials for Benazepril Hydrochloride And Hydrochlorothiazide
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00170950 ↗ | Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension | Terminated | Novartis | Phase 3 | 2003-10-01 | A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population. |
NCT00367094 ↗ | Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension | Completed | Novartis | Phase 3 | 2006-07-01 | This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult Chinese patients with mild to moderate essential hypertension. Patients whose blood pressure is not adequately controlled with benazepril monotherapy during a 4 week run-in period will be randomly allocated to double blind treatment over 8 weeks with either a combination of benazepril/hydrochlorothiazide per day or continuation of benazepril per day. |
NCT00649038 ↗ | Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2002-12-01 | The objective of this study was to investigate the bioequivalence of Mylan benazepril HCl and hydrochlorothiazide 20 mg/25 mg to Novartis Lotensin HCT® 20 mg/25 mg combination tablets following a single, oral 40 mg/50 mg (2 x 20 mg/25 mg) dose administration under fed conditions. |
NCT00649597 ↗ | Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2002-11-01 | The objective of this study was to investigate the bioequivalence of Mylan benazepril HCl and hydrochlorothiazide 20 mg/25 mg to Novartis Lotensin HCT® 20 mg/25 mg combination tablets following a single, oral 40 mg/50 mg (2 x 20 mg/25 mg) dose administration under fasting conditions. |
NCT00778674 ↗ | Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fed Conditions | Completed | Ranbaxy Laboratories Limited | N/A | 2004-10-01 | The purpose of this study was to determine the bioavailability of Benazepril and hydrochlorothiazide (HCTZ) from two Benazepril/HCTZ 20 mg/25 mg products after administration of single doses to normal healthy subjects under fed conditions. These data were to be evaluated statistically to determine if the products meet bioequivalence criteria. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Benazepril Hydrochloride And Hydrochlorothiazide
Condition Name
Clinical Trial Locations for Benazepril Hydrochloride And Hydrochlorothiazide
Trials by Country
Clinical Trial Progress for Benazepril Hydrochloride And Hydrochlorothiazide
Clinical Trial Phase
Clinical Trial Sponsors for Benazepril Hydrochloride And Hydrochlorothiazide
Sponsor Name